2025 NMD4C and MDC Neuromuscular Fellowship Funding Competition Opens
Together with Muscular Dystrophy Canada (MDC) we are excited to announce the opening of our 2025 annual funding competition to award postdoctoral fellowships in neuromuscular disease (NMD) research, and clinical fellowship awards in neuromuscular medicine and electromyography!
This annual funding competition provides salary support for early-career scientists to conduct postdoctoral studies in a laboratory focused on research of NMDs, and early-career clinicians to participate in a neuromuscular medicine and electromyography fellowship training program.
Successful applicants are eligible to receive $40 000 in funding over a one-year period for a postdoctoral fellowship, and $80 000 in funding over a one-year period for a clinical fellowship. This year, we will fund two (2) postdoctoral research fellowships and two (2) clinical fellowships.
Dates and Timelines
Funding competition opens: September 3rd, 2024
Application submission deadline: October 15th, 2024.
Eligibility and Selection Criteria
Eligibility and selection guidelines are available on the NMD4C website for both the postdoctoral research fellowship and clinical fellowships, and instructions on how to submit your application.
Postdoctoral fellowship competition guidelines
Clinical fellowship competition guidelines
If you have any questions about the 2025 competition, please contact network manager Erin Beattie at .
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.